Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 1,694 trials

Simvastatin for Primary Sclerosing Cholangitis (PSC)

We are studying whether simvastatin can help people with PSC live longer without serious complications like bile duct cancer or the need for a transplant. We will also examine its effects on disease markers and symptoms.

Primary Sclerosing Cholangitis>2 yearsEfficacy phase (II)Standard MedicinesHepatologyOncology

Ampullary Adenocarcinoma: mFOLFIRINOX vs. Gemcitabine or Capecitabine

We are studying whether a combination chemotherapy can improve survival rates for patients after surgery for ampullary adenocarcinoma. The trial also looks at quality of life and side effects compared to standard treatments.

Ampullary Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Obsessive-Compulsive Disorder: Pramipexole Treatment Study

We are investigating whether pramipexole can improve treatment outcomes for individuals with resistant OCD. The study will also assess the safety of this medication and its effects on brain function.

Obsessive-Compulsive Disorder (OCD)6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Crizotinib Safety Study for Cancer Patients

We are monitoring the safety of crizotinib for individuals who have participated in earlier studies. This research aims to ensure the continued well-being of patients using this treatment.

Solid TumorMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Senicapoc for Progressive Fibrotic Interstitial Lung Disease

We are studying whether Senicapoc can help slow the progression of lung disease in patients with progressive fibrotic ILD. This trial compares its effects to a placebo alongside standard care.

Interstitial Pulmonary Fibrosis6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

Triple Negative Breast Cancer: Imatinib Study

We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.

Triple Negative Breast CancerPrimary Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Myotonic Dystrophy: Mexiletine PR Study

We are investigating whether once daily mexiletine can help reduce muscle stiffness in patients with myotonic dystrophy types 1 and 2. The study will also look at its safety and how it affects daily activities.

Myotonic Dystrophy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Cystic Fibrosis: SPL84 Inhalation Treatment

We are testing a new inhaled medication, SPL84, for patients with cystic fibrosis to see if it is safe and how well it works. This study will help us understand its effects on this specific group of patients.

Cystic Fibrosis3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePulmonology

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Epithelial Ovarian Cancer: Letrozole Maintenance Therapy

We are studying whether letrozole can help women with epithelial ovarian cancer stay cancer-free after surgery and chemotherapy. This trial compares letrozole to a placebo to see if it improves outcomes.

Ovarian Epithelial CancerConfirmation phase (III)11-15 visitsInvestigational MedicinesGynecology and ObstetricsOncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Colorectal Polyp Removal: Anticoagulants and Antiplatelets Study

We are investigating whether continuing blood-thinning medications during polypectomy for small colorectal polyps affects bleeding risks. This study will also assess heart-related risks when these medications are stopped.

Healthy Participants Undergoing Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematology